Trial Profile
A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed Patients With Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2022
Price :
$35
*
At a glance
- Drugs Vebicorvir (Primary) ; Entecavir; Tenofovir alafenamide; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Proof of concept; Therapeutic Use
- Sponsors Assembly Biosciences
- 26 Jun 2022 Results assessing clinical evaluation of VBR 's drug-drug interaction (DDI) potential from Phase 1 (Study 103 ) and Phase 2a (NCT03577171, NCT03576066) studies, presented at The International Liver Congress 2022.
- 08 Jun 2022 According to an Assembly Biosciences media release, data from this study will be presented at the International Liver Congress, the Annual Meeting of the European Association for the Study of the Liver (EASL).
- 20 Apr 2022 Results published in the Journal of Hepatology